🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06976996
Active, not recruiting Not applicable

Efficacy of Esketamine Combined With Different General Anesthetics on Quality of Postoperative Recovery

NCT06976996 · tracked via the Priya Life Science China tracker
Sponsor
Northern Jiangsu People's Hospital
Phase
Not applicable
Started
2025-03-16
Last updated
2025-05-16

Condition(s) studied

Quality of Postoperative Recovery

Investigational drug(s) / intervention(s)

normal salineesketaminepropofoletomidate-ciprofol (EC) mixtureciprofoletomidate-propofol (EP) mixture

normal saline: normal saline (0.15 ml/kg)

esketamine: esketamine (0.15 mg/kg)

propofol: propofol (2 mg/kg)

etomidate-ciprofol (EC) mixture: etomidate-ciprofol (EC) mixture (0.2 ml/kg)

ciprofol: ciprofol (0.5 mg/kg)

etomidate-propofol (EP) mixture: etomidate-propofol (EP) mixture (0.2 ml/kg)

Study summary

To explore the effect of subanesthetic-dose esketamine combined with different general anesthetic drugs on the quality of postoperative recovery in patients undergoing painless gastrointestinal endoscopy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * (1) Aged between 18 and 75 years old (inclusive); (2) ASA (American Society of Anesthesiologists) physical status classification of Class I to III; (3) Body Mass Index (BMI) ranging from 18 to 30 kg/m²; (4) Individuals scheduled to undergo combined gastroscopy and colonoscopy under painless anesthesia; (5) Those with a patent airway and no history of difficult intubation or difficult airway management; (6) Individuals with intact cognitive function, who have provided informed consent, voluntarily participate in this study, and are capable of cooperating to complete data collection. Exclusion Criteria: * (1)A history of unregulated diabetes mellitus, hypertension, or hypotension; (2)Concomitant hyperthyroidism or hypothyroidism; (3)Concomitant psychiatric or neurological disorders; (4)Severe hepatic or renal insufficiency; (5)Concomitant glaucoma, severe hearing or visual impairment that hinders cooperation; (6)Individuals with significant organ dysfunction; (7)Those with allergies to or contraindications for the study drug; (8)Patients with aneurysmal vascular diseases involving the thoracic or abdominal aorta, intracranial arteries, or peripheral arterial vessels; (9)Individuals who are unable to cooperate in completing the Quality of Recovery-15 (QoR-15) questionnaire.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Northern Jiangsu People's Hospital Yangzhou Jiangsu

More Northern Jiangsu People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06976996 on ClinicalTrials.gov ↗ ← All trials in China